Recent progress in immunoisolated cell therapy.
Biohybrid implants represent a new class of medical device in which living cells, supported in a hydrogel matrix, and surrounded by a semipermiable membrane, produce and deliver therapeutic reagents to specific sites within a host. First proposed in the mid-1970s for diabetes, this treatment modality has progressed rapidly in the past four years and is now being investigated not just for endocrine disorders but also for alleviation of chronic pain, treatment of neurodegenerative disorders, and delivery of neurotrophic factors to sites within the blood brain barrier, and as a practical alternative to conventional ex vivo.
Lysaght
M J
MJ
CytoTherapeutics, Inc., Providence, Rhode Island 02906.
Frydel
B
B
Gentile
F
F
Emerich
D
D
Winn
S
S
D000544:Alzheimer Disease / Q000628:therapy; D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy; D000740:Anemia / Q000628:therapy; D000818:Animals; D001709:Biotechnology; D002469:Cell Separation / Q000379:methods*; D017690:Cell Transplantation / Q000379:methods; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy; D004392:Dwarfism / Q000628:therapy; D002836:Hemophilia B / Q000628:therapy; D006801:Humans; D007158:Immunologic Techniques; D059408:Pain Management; D010300:Parkinson Disease / Q000628:therapy; D019736:Prostheses and Implants; D014183:Transplantation, Heterologous